Agenda - Day 1 | EU Pharmaceutical Law Forum

Showing 1 of 1 Streams

Registration

08:00 - 08:40

Registration

Showing 1 of 1 Streams

Competition and US Policy Implications in Europe

08:40 - 08:50

Chair’s Opening Remarks

08:50 - 09:05

Review of Recent Developments in European and Global Antitrust Trends

Mélanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP

09:05 - 09:35

KEYNOTE Update from EU Commission on Competition Law Enforcement

Recent updates on competition law enforcement in the EU pharmaceutical sector
Current and future focus for 2026 and beyond

Inge Bernaerts - Director of Policy & Strategy, DG Comp, European Commission

09:35 - 10:05

Decoding the Teva Copaxone Decision: Practical Implications on How you Communicate about your Competitors

In depth assessment and key takeaways following the publication of the decision
How far can originators go and what is the scope for generic manufacturers to challenge this?

Aileen Murtagh - Legal Counsel, Biomarin
James Killick - Partner, White and Case

10:05 - 10:35

Competition Law Consideration for the Exchange of Commercially Sensitive Information

Update on antitrust violation trends in the exchange of information: from no-poach agreements and wage fixing to collusion on pricing, sustainability and ESG discussions
Belgium authority guidance on exchange for pricing and reimbursement information for combination therapies: how far can you go in exchanging information?
Practical advice on how to engage with competitors and customers

Amalia Athanasiadou - Lead Counsel, CSL Vifor
Strati Sakellariou-Witt - Partner, White & Case

Showing 1 of 1 Streams

Networking

10:35 - 11:10

Networking Break

Showing 1 of 1 Streams

Competition and US Policy Implications in Europe

11:10 - 11:50

New Developments in Merger Control

Update on new merger guidelines, national approaches and calls for new call-in powers
Current approaches to killer acquisitions
Key learning from Novo Holdings acquisition of Catalent: the importance of scale, role of efficiencies and innovation and the implications for merger guidelines
Navigating the uncertainty around commercial transactions: are there risks posed by even minor interests in acquisitions?

Ulla Schwager - Head of Unit E1, European Commission
Elina Koustoumpardi - Senior Consultant, Charles River Associates
Héctor Armengod - Partner, Latham & Watkins

11:50 - 12:20

How to Respond to Dawn Raids and Investigations

Strategic insights for in-house teams: how to respond internally and externally, ensuring preparedness and effective responses to dawn raids and investigations
Discussion on the Michelin, Symrise, and Alchem International cases: broader implications for challenging dawn raids and investigations
The use of AI technology used by EU Commission and how companies can prepare

Alice Ruzza - Antitrust and Public Affairs Counsel, Sandoz

12:20 - 13:00

ENFORCERS’ ROUNDTABLE Priorities and Focus

Competition authority priorities and focus for 2026 and beyond on antitrust matters
Updates on competition authority activity levels

Anne-Charlotte Prévot - Co-ordinator for Health & Pharma Task Force, Belgian Competition Authority
Mélanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP
Ulla Schwager - Head of Unit E1, European Commission
Luca Arnaudo - Senior Officer, AGCM - Italian Competition Authority

Showing 1 of 1 Streams

Networking

13:00 - 14:30

Networking Lunch

Showing 1 of 1 Streams

Competition and US Policy Implications in Europe

14:30 - 15:00

US Policy Latest: Recent Updates and Long-Term Implications for Europe

Approaches to the pharmaceutical sector under the current US Administration
Understanding policy rolled out, timelines and expectations
Latest on Most Favoured Nations (MFNs) and TrumpRX

Senior Partner - ,, Arnold & Porter

15:00 - 15:40

PRICING DEVELOPMENTS Regulatory and Antitrust Pricing Considerations in Response to Trump 2.0

General implications for product launch, pricing, and trade, with a focus on countries with high GDPs that typically set lower list prices under MFN policies
Cross-market impacts of MFN: US price cuts, EU pricing pressure, and implications for launch and alternative access routes
Pricing strategy levers: confidential pricing, options to renegotiate prices, impact on pricing new products and re-evaluating launch sequences between US vs EU

Brian Savage - Senior Vice-President and General Counsel, Global Litigation, Teva Pharmaceuticals
Jennifer Ulbrich - Senior Legal Counsel, Roche
Alexandru Potlog - Senior Counsel, Global Legal Strategies & Policy, AbbVie

Showing 1 of 1 Streams

Networking

15:40 - 16:10

Networking Break

Showing 1 of 1 Streams

Competition and US Policy Implications in Europe

16:10 - 16:50

SUPPLY STRATEGY Obligation to Supply, Parallel Trade and Distribution

Examining a manufacturers obligation to supply
Update on recent cases addressing parallel trade and their impact
Practical scenarios when navigating parallel trade: the fine line between what is and isn’t acceptable
Pharmaceutical legislation, Critical Medicines Act and State Aid implications on supply
Effective distribution strategies in the pharmaceutical sector

Niels van Nuland - International Competition Law Counsel, Senior Director Legal, Gilead
Michael Clancy - Partner, Van Bael & Bellis

16:50 - 17:30

TRADE AND TARIFFS Evolving Customs and Tariffs Landscape for Pharmaceuticals

Understanding the tariff landscape and practical mitigation strategies
Opportunities around the origin of goods, reclassifying products, utilising trade agreements, and potentially optimising the valuation of goods
Practical implications and considerations for in-house teams

Philippe Heeren - Partner, Reed Smith

17:30 - 17:35

Close of Day 1

Day 1Monday, 19 May 2025 - CET/CEST (Cent Europe Summer, GMT+2)

Register Interest for 2025